BELMONT, Calif., March 5, 2012 /PRNewswire/ -- Phalanx Biotech Group, a global genomic products and service provider, manufactures the OneArray® line of open-platform microarrays for whole genome gene expression and microRNA profiling. Driven by several new product launches in 2011, Phalanx Biotech reported revenue growth across all its major geographical markets. "2011 proved to be a very busy year for our manufacturing team with microarray launches of the Rat OneArray®, Rice OneArray®, and microRNA OneArray® and completion of several custom ODM projects," said Richard Su, Ph.D., Head of Product Development. "We anticipate 2012 to be equally busy with manufacturing runs already scheduled for an updated microRNA microarray and a focused cytogenetic microarray. Importantly, we continue to maintain a bullish stance on the utilization of microarrays for discovery research and clinical applications."
"PhalanxBio, Inc., a wholly-owned, US subsidiary of Phalanx Biotech Group, achieved record 2011 sales in its target markets of North America and Europe – growing revenues more than 20% year over year," announced Shengwan Lee, Ph.D., President and CEO. "Our growth in this highly competitive marketplace is a strong testament by our customers of the performance and value of our OneArray® microarray products and services. To underscore our commitment to delivering the highest quality products and services, I am also pleased to announce our recent ISO:9001:2008 and 13485:2003 certification – a validation of our adherence to the rigorous quality management systems at Phalanx Biotech."
About Phalanx Biotech Group
Phalanx Biotech Group, with operations in California, Taiwan and China, provides genomics products and services worldwide to academic, clinical, pharmaceutical and biotech communities. Built on world-class, integrated-chip foundry technology, Phalanx Biotech has developed the
|SOURCE Phalanx Biotech Group|
Copyright©2010 PR Newswire.
All rights reserved